SGLT2 inhibitors can slow progression of chronic kidney disease

(ERA-EDTA) The CREDENCE trial [3] provided evidence that the SGLT2 inhibitor Canagliflozin slows the progression of CKD in individuals with type 2 diabetes (T2D) and CKD with albuminuria. The Phase III DAPA-CKD trial [1] has now shown that the SGLT2 inhibitor Dapagliflozin can significantly slow CKD progression in all CKD patients, not only in those with diabetes. This breakthrough in kidney disease treatment goes back to an incidental study finding of Professor Christoph Wanner, President of the ERA-EDTA.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news

Related Links:

Objectives: Long-term visit-to-visit SBP variability (VVV) predicts cerebro-cardiovascular and renal events in patients with hypertension. Whether VVV predicts hypertension and/or chronic kidney disease is currently unknown. We assessed the role of VVV on the development of hypertension and changes in renal function in patients with type 2 diabetes and normal blood pressure (NBP) in a real-life clinical setting. Methods: Clinical records from 8998 patients with type 2 diabetes, NBP, and normal estimated glomerular filtration rate (eGFR) were analyzed. VVV was measured by SD of the mean SBP recorded in at least four vi...
Source: Journal of Hypertension - Category: Cardiology Tags: ORIGINAL PAPERS: BP in specific clinical conditions Source Type: research
Chronic kidney disease (CKD) represents a frequent co-morbidity of type 2 diabetes mellitus (T2DM), affecting 30-50% of all patients, while diabetes is the leading cause of end-stage kidney disease (ESKD) worldwide.1,2 Vice versa, incidence rates of T2DM among patients with CKD are significantly higher compared to the general population.3 Sufficient glycemic control is required for all patients suffering from CKD and TDM; however, very strict control has been shown to increase all-cause mortality similarly to insufficient control.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research
ConclusionsMetformin use is connected with significantly less risks of all-cause mortality and cardiovascular events in patients with T2DM and mild/moderate CKD. However, RCTs with large sample sizes are warranted in the future to assess whether these key benefits extend to later stages of CKD by dose adjustment.
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
AbstractDiabetic kidney disease (DKD) occurs in approximately 20 –40% of patients with type 2 diabetes mellitus. Patients with DKD have a higher risk of cardiovascular and all-cause mortality. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and antihyperglycemic drugs form the mainstay of DKD management and aim to restrict progression to more severe stages of DKD. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) control hyperglycemia by blocking renal glucose reabsorption in addition to preventing inflammation, thereby improving endothelial function and reducing oxidative stress; consequen...
Source: Diabetes Therapy - Category: Endocrinology Source Type: research
In the original article, the Table 1 has published with error.
Source: Diabetes Therapy - Category: Endocrinology Source Type: research
Conclusion: Addition of eplerenone to ACEI shows an added antialbuminuric effect without significant change of the serum K level compared with eplerenone or ACEI.Cardiorenal Med
Source: Cardiorenal Medicine - Category: Urology & Nephrology Source Type: research
SGLT2 inhibitors and GLP-1 receptor agonists should be considered in people with type 2 diabetes and chronic kidney disease to protect against heart disease and kidney disease progression, the AHA says.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Source Type: news
ConclusionComplications frequently occur in EPN patients as compared to pyelonephritis.
Source: Journal of Diabetes and Metabolic Disorders - Category: Endocrinology Source Type: research
lar Biology; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; and Council on Lifestyle and Cardiometabolic Health Abstract Chronic kidney disease (CKD) with type 2 diabetes (T2D) is a major public health problem, resulting in significant cardiovascular and kidney adverse outcomes worldwide. Despite the widespread use of standard-of-care therapies for CKD with T2D over the past few decades, rates of progression to end-stage kidney disease remain high with no beneficial impact on its accompanying burden of cardiovascular disease. The advent of the newer classes of antihyperglycemic agent...
Source: Circulation - Category: Cardiology Authors: Tags: Circulation Source Type: research
AbstractEpidemiological studies have documented a high incidence of diabetes in hypertensive patients.Insulin resistance is defined as a less than expected biologic response to a given concentration of the hormone and plays a pivotal role in the pathogenesis of diabetes. However, over the last decades, it became evident that insulin resistance is not merely a metabolic abnormality, but is a complex and multifaceted syndrome that can also affect blood pressure homeostasis. The dysregulation of neuro-humoral and neuro-immune systems is involved in the pathophysiology of both insulin resistance and hypertension. These mechani...
Source: High Blood Pressure and Cardiovascular Prevention - Category: Cardiology Source Type: research
More News: Canagliflozin | Chronic Kidney Disease | Dapagliflozin | Diabetes | Diabetes Type 2 | Endocrinology | Forxiga | International Medicine & Public Health | Invokana | SGLT2 Inhibitors | Study | Urology & Nephrology